Monographie - Ceftobiprole medocaril sodium

Viimeisin päivitys :
16/12/2025

Ceftobiprole medocaril sodium

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Adaluzis	Irlanti
Mabelio	Ranska
Zevtera	Espanja, Iso-Britannia, Marokko, Meksiko, Norja, Ruotsi, Saksa, Suomi, Sveitsi

Viitteet : Ceftobiprole medocaril sodium

	tyyppi	julkaisu
2269	Lehti	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3520	Laboratorio	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratorio	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratorio	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratorio	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
5098	Lehti	Esteban‑Cartelle B, Anaya B.J, Menéndez‑Conde C.P, Vicente‑Oliveros N , Serrano D.R, Álvarez‑Díaz A. Stability of Ceftobiprole Medocaril in Portable Elastomeric Infusion Devices. Infect Dis Ther 2025 ; 14:1685–1696.

Mentions Légales